Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol
We present a case of a female patient who developed acute onset of visual loss due to central serous retinopathy as a consequence of steroid premedication for docetaxol given as second line neoadjuvant chemotherapy for breast cancer. Central serous retinopathy is a recognised association with steroi...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2008-01-01
|
Series: | Clinical Medicine Insights: Oncology |
Online Access: | https://doi.org/10.4137/CMO.S339 |
id |
doaj-fe10617c02ef4b7caabe4bdffc4f77c3 |
---|---|
record_format |
Article |
spelling |
doaj-fe10617c02ef4b7caabe4bdffc4f77c32020-11-25T03:24:02ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492008-01-01210.4137/CMO.S339Acute Visual Loss Induced by Dexamethasone during Neoadjuvant DocetaxolD.L. Gregory0C.D. Jones1E.R.E. Denton2A.N. Harnett3Department of Oncology, Addenbrookes Hospital, Cambridge, UK.Department of Ophthalmology, Norfolk and Norwich University Hospital Norwich, UK.Department of Radiology, Norfolk and Norwich University Hospital Norwich, UK.Department of Oncology, Norfolk and Norwich University Hospital Norwich, UK.We present a case of a female patient who developed acute onset of visual loss due to central serous retinopathy as a consequence of steroid premedication for docetaxol given as second line neoadjuvant chemotherapy for breast cancer. Central serous retinopathy is a recognised association with steroids but has not been previously reported in association with the management of solid tumours. Reduction in steroid dose and duration permitted recovery of her visual acuity while allowing completion of the prescribed chemotherapy regimen. An overview of the presentation, pathogenesis, aetiologies and management of central serous retinopathy is given.https://doi.org/10.4137/CMO.S339 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
D.L. Gregory C.D. Jones E.R.E. Denton A.N. Harnett |
spellingShingle |
D.L. Gregory C.D. Jones E.R.E. Denton A.N. Harnett Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol Clinical Medicine Insights: Oncology |
author_facet |
D.L. Gregory C.D. Jones E.R.E. Denton A.N. Harnett |
author_sort |
D.L. Gregory |
title |
Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol |
title_short |
Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol |
title_full |
Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol |
title_fullStr |
Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol |
title_full_unstemmed |
Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol |
title_sort |
acute visual loss induced by dexamethasone during neoadjuvant docetaxol |
publisher |
SAGE Publishing |
series |
Clinical Medicine Insights: Oncology |
issn |
1179-5549 |
publishDate |
2008-01-01 |
description |
We present a case of a female patient who developed acute onset of visual loss due to central serous retinopathy as a consequence of steroid premedication for docetaxol given as second line neoadjuvant chemotherapy for breast cancer. Central serous retinopathy is a recognised association with steroids but has not been previously reported in association with the management of solid tumours. Reduction in steroid dose and duration permitted recovery of her visual acuity while allowing completion of the prescribed chemotherapy regimen. An overview of the presentation, pathogenesis, aetiologies and management of central serous retinopathy is given. |
url |
https://doi.org/10.4137/CMO.S339 |
work_keys_str_mv |
AT dlgregory acutevisuallossinducedbydexamethasoneduringneoadjuvantdocetaxol AT cdjones acutevisuallossinducedbydexamethasoneduringneoadjuvantdocetaxol AT eredenton acutevisuallossinducedbydexamethasoneduringneoadjuvantdocetaxol AT anharnett acutevisuallossinducedbydexamethasoneduringneoadjuvantdocetaxol |
_version_ |
1724603772124004352 |